Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Cell type-specific responses of human cells to inhibition of replication licensing

Oncogene volume 21, pages 6624–6632 (2002)Cite this article

Abstract

Replication origins are ‘licensed' for a single initiation event by loading Mcm2-7 complexes during late mitosis and G1. Licensing is blocked at other cell cycle stages by the activity of cyclin-dependent kinases and a small protein called geminin. Here, we describe the effects of over-expressing a non-degradable form of geminin in various cell lines. Geminin expression reduced the quantity of Mcm2 bound to chromatin and blocked cell proliferation. U2OS (p53+/Rb+) cells showed an early S phase arrest with high cyclin E and undetectable cyclin A levels, consistent with the activation of an intra-S checkpoint. Saos2 (p53-/Rb-) cells showed an accumulation of cells in late S and G2/M with approximately normal levels of cyclin A, consistent with loss of this intra-S phase checkpoint. Geminin also induced apoptosis in both these cell lines. In contrast, IMR90 primary fibroblasts over-expressing geminin arrested in G1 with reduced cyclin E levels and no detectable apoptosis. A ‘licensing checkpoint’ may therefore act in primary cells to prevent passage into S phase in the absence of sufficient origin licensing. These results suggest that inhibition of the licensing system may cause cancer-specific cell killing and therefore represent a novel anti-cancer target.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8

Similar content being viewed by others

References

  • Abraham RT . 2001 Genes Dev. 15: 2177–2196

  • Arentson E, Faloon P, Seo J, Moon E, Studts JM, Fremont DH, Choi K . 2002 Oncogene 21: 1150–1158

  • Blow JJ, Hodgson B . 2002 Trends Cell Biol. 12: 72–78

  • Blow JJ, Laskey RA . 1988 Nature 332: 546–548

  • Burkhart R, Schulte D, Hu D, Musahl C, Gohring F, Knippers R . 1995 Eur. J. Biochem. 228: 431–438

  • Chew YP, Ellis M, Wilkie S, Mittnacht S . 1998 Oncogene 17: 2177–2186

  • Diffley JF, Cocker JH, Dowell SJ, Rowley A . 1994 Cell 78: 303–316

  • Diffley JFX . 2001 Curr. Biol. 11: R367–R370

  • Dimitrova DS, Gilbert DM . 2000 Nature Cell Biol. 2: 686–694

  • Donovan S, Harwood J, Drury LS, Diffley JF . 1997 Proc. Natl. Acad. Sci. USA 94: 5611–5616

  • Feijoo C, Hall-Jackson C, Wu R, Jenkins D, Leitch J, Gilbert DM, Smythe C . 2001 J. Cell Biol. 154: 913–923

  • Gillespie PJ, Li A, Blow JJ . 2001 BioMed Central Biochem. 2: 15

  • Guo N, Faller DV, Vaziri C . 2000 J. Biol. Chem. 275: 1715–1722

  • Harrington EA, Bruce JL, Harlow E, Dyson N . 1998 Proc. Natl. Acad. Sci. USA 95: 11945–11950

  • He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B . 1998 Proc. Natl. Acad. Sci. USA 95: 2509–2514

  • Hodgson B, Li A, Tada S, Blow JJ . 2002 Curr. Biol. 12: 678–683

  • Hua XH, Newport J . 1998 J. Cell Biol. 140: 271–281

  • Knudsen ES, Buckmaster C, Chen TT, Feramisco JR, Wang JY . 1998 Genes Dev. 12: 2278–2292

  • Knudsen KE, Booth D, Naderi S, Sever-Chroneos Z, Fribourg AF, Hunton IC, Feramisco JR, Wang JY, Knudsen ES . 2000 Mol. Cell. Biol. 20: 7751–7763

  • Labib K, Diffley JF . 2001 Curr. Opin. Genet. Dev. 11: 64–70

  • Labib K, Kearsey SE, Diffley JF . 2001 Mol. Biol. Cell 12: 3658–3667

  • Lei M, Kawasaki Y, Tye BK . 1996 Mol. Cell. Biol. 16: 5081–5090

  • Lei M, Tye BK . 2001 J. Cell Sci. 114: 1447–1454

  • Mahbubani HM, Chong JP, Chevalier S, Thömmes P, Blow JJ . 1997 J. Cell Biol. 136: 125–135

  • Maine GT, Sinha P, Tye BK . 1984 Genetics 106: 365–385

  • Maiorano D, Moreau J, Mechali M . 2000 Nature 404: 622–625

  • McGarry TJ, Kirschner MW . 1998 Cell 93: 1043–1053

  • Midgley CA, Desterro JM, Saville MK, Howard S, Sparks A, Hay RT, Lane DP . 2000 Oncogene 19: 2312–2323

  • Miura M, Sasaki T . 1999 Methods Mol. Biol. 113: 577–582

  • Musahl C, Holthoff HP, Lesch R, Knippers R . 1998 Exp. Cell Res. 241: 260–264

  • Nishitani H, Taraviras S, Lygerou Z, Nishimoto T . 2001 J. Biol. Chem. 276: 44905–44911

  • Quinn LM, Herr A, McGarry TJ, Richardson H . 2001 Genes Dev. 15: 2741–2754

  • Rowles A, Tada S, Blow JJ . 1999 J. Cell Sci. 112: 2011–2018

  • Santocanale C, Diffley JFX . 1998 Nature 395: 615–618

  • Saudan P, Vlach J, Beard P . 2000 EMBO J. 19: 4351–4361

  • Sever-Chroneos Z, Angus SP, Fribourg AF, Wan H, Todorov I, Knudsen KE, Knudsen ES . 2001 Mol. Cell. Biol. 21: 4032–4045

  • Shirahige K, Hori Y, Shiraishi K, Yamashita M, Takahashi K, Obuse C, Tsurimoto T, Yoshikawa H . 1998 Nature 395: 618–621

  • Stoeber K, Mills AD, Kubota Y, Krude T, Romanowski P, Marheineke K, Laskey RA, Williams GH . 1998 EMBO J. 17: 7219–7229

  • Stoeber K, Tisty TD, Happerfield L, Thomas GA, Romanov S, Bobrow L, Williams ED, Williams GH . 2001 J. Cell Sci. 114: 2027–2041

  • Sun W, Hola M, Pedley K, Tada S, Blow JJ, Todorov IT, Kearsey SE, Brooks RF . 2000 J. Cell Sci. 113: 683–695

  • Tada S, Li A, Maiorano D, Méchali M, Blow JJ . 2001 Nature Cell Biol. 2: 107–113

  • Tan D-F, Huberman JA, Hyland A, Loewen GM, Brooks JSJ, Beck AF, Todorov IT, Bepler G . 2001 BioMed Central Cancer 1: 6

  • Todorov IT, Attaran A, Kearsey SE . 1995 J. Cell Biol. 129: 1433–1445

  • Tsuruga H, Yabuta N, Hashizume K, Ikeda M, Endo Y, Nojima H . 1997 Biochem. Biophys. Res. Commun. 236: 118–125

  • Wohlschlegel JA, Dwyer BT, Dhar SK, Cvetic C, Walter JC, Dutta A . 2000 Science 290: 2309–2312

  • Wohlschlegel JA, Kutok JL, Weng AP, Dutta A . 2002 Am. J. Pathol. 161: 267–273

  • Woodward A, Li A, Blow JJ . 2002 Chemtracts (in press)

Download references

Acknowledgements

We thank Neil Perkins, Pedro Jares, Pamela Robertson, Jean Christophe Bourdon and Marcus Achison for help at various stages of this project. This work is the subject of UK patent application 0209508.1. This work was supported by a British Commonwealth scholarship to S Shreeram and Cancer Research UK grant SP2385/0101.

Author information

Authors and Affiliations

  1. Wellcome Trust Biocentre, University of Dundee, Dow Street, Dundee DD1 5EH, UK

    S Shreeram & J Julian Blow

  2. Department of Surgery and Molecular Oncology, University of Dundee, Ninewells Hospital and Medical School, Dundee, DD1 9SY, UK

    S Shreeram, Alison Sparks & David P Lane

Authors
  1. S Shreeram
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alison Sparks
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David P Lane
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J Julian Blow
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J Julian Blow.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shreeram, S., Sparks, A., Lane, D. et al. Cell type-specific responses of human cells to inhibition of replication licensing. Oncogene 21, 6624–6632 (2002). https://doi.org/10.1038/sj.onc.1205910

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1205910

Keywords

This article is cited by

Search

Advanced search

Quick links